JP7674628B2 - インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 - Google Patents

インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 Download PDF

Info

Publication number
JP7674628B2
JP7674628B2 JP2018543599A JP2018543599A JP7674628B2 JP 7674628 B2 JP7674628 B2 JP 7674628B2 JP 2018543599 A JP2018543599 A JP 2018543599A JP 2018543599 A JP2018543599 A JP 2018543599A JP 7674628 B2 JP7674628 B2 JP 7674628B2
Authority
JP
Japan
Prior art keywords
treatment
hdv
interferon lambda
patient
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505553A (ja
JP2019505553A5 (enExample
Inventor
エドゥアルド・ブルーノ・マーティンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIT Pharma Inc
Original Assignee
EIT Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EIT Pharma Inc filed Critical EIT Pharma Inc
Publication of JP2019505553A publication Critical patent/JP2019505553A/ja
Publication of JP2019505553A5 publication Critical patent/JP2019505553A5/ja
Priority to JP2022140259A priority Critical patent/JP2022172279A/ja
Priority to JP2024125792A priority patent/JP2024156840A/ja
Application granted granted Critical
Publication of JP7674628B2 publication Critical patent/JP7674628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018543599A 2016-02-19 2017-02-17 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 Active JP7674628B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022140259A JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297759P 2016-02-19 2016-02-19
US62/297,759 2016-02-19
PCT/US2017/018466 WO2017143253A1 (en) 2016-02-19 2017-02-17 Treatment of hepatitis delta virus infection with interferon lambda

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022140259A Division JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Publications (3)

Publication Number Publication Date
JP2019505553A JP2019505553A (ja) 2019-02-28
JP2019505553A5 JP2019505553A5 (enExample) 2020-03-26
JP7674628B2 true JP7674628B2 (ja) 2025-05-12

Family

ID=59625481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543599A Active JP7674628B2 (ja) 2016-02-19 2017-02-17 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2022140259A Pending JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A Pending JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022140259A Pending JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A Pending JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Country Status (17)

Country Link
US (1) US10953072B2 (enExample)
EP (2) EP3957319B1 (enExample)
JP (3) JP7674628B2 (enExample)
KR (1) KR20180110127A (enExample)
CN (1) CN108883156A (enExample)
CY (1) CY1124220T1 (enExample)
DK (1) DK3416675T3 (enExample)
ES (2) ES3008560T3 (enExample)
HR (1) HRP20210862T1 (enExample)
HU (1) HUE055343T2 (enExample)
LT (1) LT3416675T (enExample)
PL (1) PL3416675T3 (enExample)
PT (1) PT3416675T (enExample)
RS (1) RS61944B1 (enExample)
SI (1) SI3416675T1 (enExample)
SM (1) SMT202100335T1 (enExample)
WO (1) WO2017143253A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
ES3008560T3 (en) 2016-02-19 2025-03-24 Eit Pharma Inc Treatment of hepatitis delta virus infection with interferon lambda
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
US20210187073A1 (en) * 2018-08-23 2021-06-24 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
WO2021034101A1 (ko) * 2019-08-21 2021-02-25 한국과학기술원 신규 인터페론 람다 변이체 및 이의 제조방법
CN114555079A (zh) * 2019-10-16 2022-05-27 艾格尔峰生物制药有限公司 治疗丁型肝炎病毒感染的方法
US20230285510A1 (en) * 2020-02-06 2023-09-14 Eiger Biopharmaceuticals, Inc. Treatment of coronavirus infection with interferon lambda

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4377126B2 (ja) 2000-06-30 2009-12-02 ザイモジェネティクス，インコーポレイティド インターフェロン−様タンパク質ｚｃｙｔｏ２１
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
JP4987001B2 (ja) 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
EP1912668A2 (en) 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
SI1931704T1 (sl) 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
JP2010504909A (ja) 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
CN105535961A (zh) 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
SG10201605265TA (en) * 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
CN111329989A (zh) 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
HUE044606T2 (hu) * 2014-05-01 2019-11-28 Eiger Biopharmaceuticals Inc A hepatitis delta vírusfertõzés kezelése
ES2844629T3 (es) * 2015-11-04 2021-07-22 Eiger Biopharmaceuticals Inc Tratamiento de la infección por el virus de la hepatitis delta
ES3008560T3 (en) 2016-02-19 2025-03-24 Eit Pharma Inc Treatment of hepatitis delta virus infection with interferon lambda
US20210187073A1 (en) 2018-08-23 2021-06-24 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｇｉｅｒｓｃｈ、Ｋ．、ｅｔ ａｌ．、Ｐｅｇｙｌａｔｅｄ Ｉｎｔｅｒｆｅｒｏｎ Ｌａｍｂｄａ ｅｆｆｉｃｉｅｎｔｌｙ ｓｕｐｐｒｅｓｓｅｓ ＨＤＶ ｐｒｏｄｕｃｔｉｖｉｔｙ ａｎｄ ｓｈｏｗｓ ｃｏｍｐａｒａｂｌｅ ａｂｉｌｉｔｙ ｔｏ ｉｎｄｕｃｅ ＩＳＧｓ ａｓ ｐｅｇ－ＩＦＮα ｉｎ ＨＢＶ／ＨＤＶ ｃｏ－ｉｎｆｅｃｔｅｄ ｈｕｍａｎｉｚｅｄ ｍｉｃｅ、ＥＡＳＬ ＭｏｎｏｔｈｅｍａｔｉｃＣｏｎｆｅｒｅｎｃｅ ｏｎ Ｔｒａｎｓｌａｔｉｏｎａｌ Ｒｅｓｅａｒｃｈ ｉｎ Ｖｉｒａｌ Ｈｅｐａｔｉｔｉｓ ｉｎ Ｌｙｏｎ、Ｆｒａｎｃｅ、２０１３、＜ｈｔｔｐ：／／ｗｗｗ．ｅｉｇｅｒｂｉｏ．ｃｏｍ／ｒｅｓｏｕｒｃｅｓ／Ｇｉｅｒｓｃｈ－ＥＡＳＬ－２０１３．ｐｄｆ＞

Also Published As

Publication number Publication date
EP3957319A1 (en) 2022-02-23
ES3008560T3 (en) 2025-03-24
KR20180110127A (ko) 2018-10-08
RS61944B1 (sr) 2021-07-30
HRP20210862T1 (hr) 2021-09-17
JP2019505553A (ja) 2019-02-28
EP3416675B1 (en) 2021-03-24
PT3416675T (pt) 2021-06-14
CY1124220T1 (el) 2022-05-27
US20210228686A1 (en) 2021-07-29
JP2022172279A (ja) 2022-11-15
PL3416675T3 (pl) 2021-10-11
LT3416675T (lt) 2021-06-25
HUE055343T2 (hu) 2022-05-28
US20190111110A1 (en) 2019-04-18
SMT202100335T1 (it) 2021-07-12
EP3416675B9 (en) 2021-07-14
DK3416675T3 (da) 2021-06-14
WO2017143253A1 (en) 2017-08-24
SI3416675T1 (sl) 2021-09-30
CN108883156A (zh) 2018-11-23
JP2024156840A (ja) 2024-11-06
US10953072B2 (en) 2021-03-23
EP3416675A4 (en) 2020-01-08
ES2874592T3 (es) 2021-11-05
EP3416675A1 (en) 2018-12-26
EP3957319B1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
JP7674628B2 (ja) インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
Yuen et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection
JP7571008B2 (ja) インターフェロンラムダでのデルタ肝炎ウイルス感染処置
Antonelli et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy
DK2694087T3 (en) The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
JP2014532657A (ja) Ｃ型肝炎ウイルスを処置するための方法および組成物
EP4045034A1 (en) Methods to treat hepatitis delta viral infections
US12508297B2 (en) Treatment of hepatitis delta virus infection with interferon lambda
WO2024223797A1 (en) Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
WO2024123860A9 (en) Methods to treat hepatitis delta viral infections
WO2022115765A1 (en) Treatment of hepatitis e virus infection with interferon lambda
WO2021170741A1 (en) Treatment of hbv
JP2015509980A (ja) Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
US20140335052A1 (en) Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250319

R150 Certificate of patent or registration of utility model

Ref document number: 7674628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150